Replication FailureOpen accessMedicine· cited by 9

Once-weekly semaglutide versus placebo in patients with alcohol use disorder and comorbid obesity: a randomised, double-blind, placebo-controlled trial

Mette Kruse Klausen; Signe Justesen; Julie Niemann Pedersen; Line Rasmussen; Andreas Jensen; Mathias E. Jensen; Ulla Knorr; M Bergmann · 2026 · The Lancet

WASTE classifies this as Replication Failure · AI classification, approximate

A previously reported effect did not replicate here — verify it holds before you build on it.

Abstract

BACKGROUND: Alcohol use disorder accounts for 5% of deaths worldwide annually, and there is an urgent need for new therapeutic interventions. Preclinical and initial human studies indicate that the GLP-1 receptor agonist semaglutide might reduce alcohol drinking. This study evaluated the efficacy of semaglutide once-weekly in treatment-seeking patients with alcohol use disorder and comorbid obesity. METHODS: In a 26-week, single-centre, randomised, double-blinded, placebo-controlled trial, treatment-seeking participants with moderate to severe alcohol use disorder and comorbid obesity were ass

Abstract by Mette Kruse Klausen; Signe Justesen; Julie Niemann Pedersen; Line Rasmussen; Andreas Jensen; Mathias E. Jensen; Ulla Knorr; M Bergmann, The Lancet (2026) — licensed CC BY 4.0.

Read the full paper (open access)